NeOnc’s $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA
DENVER, Sept. 16, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ: NTHI) executives put even more personal capital behind the company, following positive Phase 2a results for its experimental brain-cancer therapy NEO100.
The latest purchase brings the total open-market buying by two senior executives to approximately $629,000 since the company announced its Phase 2a results on August 12.
CEO, President and Executive Chairman Amir F. Heshmatpour purchased another 35,000 shares on September 15 for approximately $115,400, at a weighted average price of roughly $3.30 per share. That pushes his post-results purchases to 111,000 shares for approximately $418,700, at an average cost of about $3.77 per share.
Founder, Chief Medical Officer and Chief Scientific Officer Thomas C. Chen, MD, PhD, purchased another 49,016 shares for approximately $210,000. Combined, the two executives have now purchased 160,016 shares for approximately $629,000, according to the company, and all of the purchases were made in the open market with personal funds.
Heshmatpour said the buying reflects his conviction following the clinical results, “The strength of our Phase 2a results reinforces my conviction in NeOnc’s mission and the potential of our NEO platform,” he said. Heshmatpour added that his latest purchases bring his personal investment in NeOnc shares to more than $1.5 million over the past year.
The insider buying comes against the backdrop of a potentially important clinical milestone, as NeOnc reported that its NEO100-01 Phase 2a study met its primary endpoint, with six-month progression-free survival of 48.9%, compared with a pre-specified 20% benchmark for standard of care. The company reported a p-value of 0.0047 and median overall survival of 26.09 months.
NEO100 is being developed for central nervous system cancers, an area where treatment remains particularly challenging because of the blood-brain barrier. NeOnc’s platform is designed around drug candidates and delivery approaches intended to address that barrier.
The company is not putting all of its clinical ambitions behind a single candidate. Its second program, NEO212, has completed Phase 1 dose escalation and established a recommended Phase 2 dose, giving NeOnc another potential development catalyst.
Meanwhile, the company recently announced a $15 million registered direct offering, providing additional capital as it advances its clinical programs.
That combination, positive Phase 2a data, substantial open-market insider purchases, fresh financing and another clinical program moving toward Phase 2, has put NTHI at an important inflection point and the message from management is unmistakable: executives are continuing to commit their own money to the company after the NEO100 readout.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
About 24/7 Market News
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
